Your session is about to expire
← Back to Search
Cabozantinib for Meningioma
Study Summary
This trial is testing if cabozantinib, a drug typically used to treat thyroid and kidney cancers, is effective in treating meningioma, a type of brain tumor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any major health issues that are not under control.You are allergic to cabozantinib or any ingredients in it.I am able to live my life with varying degrees of assistance.Patients must have a detectable disease according to specific criteria.Your blood clotting time is within a certain range based on the lab's normal results.I have been diagnosed with meningioma, regardless of its severity.My blood counts meet the required levels without needing help from treatments.My kidneys work well enough, with a filtration rate of at least 30 ml/min.I haven't had any cancer treatment in the last 4 weeks.I have never had a brain condition caused by high blood pressure.You have had a positive test for hepatitis C virus (HCV) or hepatitis B virus (HBV) infection.I do not have a serious wound, ulcer, or bone fracture that needed treatment in the last 28 days.I am currently taking blood thinners.I need frequent procedures to remove excess fluid from my body.I need IV fluids or a feeding tube due to a blockage in my digestive system.Your heart's electrical activity, called the QT interval, is longer than 500 milliseconds.My side effects from previous treatments are mild or being managed.I am willing and able to follow the trial's treatment plan and attend all scheduled visits.My cancer came back or got worse more than 6 months after standard treatment, or I can't have these treatments.I haven't taken any kinase inhibitor medication in the last 2 weeks.My liver is functioning within the required limits.I have a history of congenital QT syndrome.I am under 18 years old.I have not had an irregular heartbeat in the last 6 months.I am currently on IV antibiotics for an infection.Your urine has too much protein in it.I am a woman who can have children and have a negative pregnancy test.Your heart's pumping ability, measured by echocardiogram, is less than or equal to 50%. If the quality of the echocardiogram is not good enough, another test called multi-gated acquisition scan (MUGA) will be done to check your heart's pumping ability.I have a history of unusual bleeding or clotting disorders.I have been treated with cabozantinib before.I have no other cancers needing treatment besides the one being studied.I can swallow pills and don't have issues with absorbing nutrients.Your blood albumin level is 2.8 grams per deciliter or higher.
- Group 1: Cabozantinib
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the recruitment quota for this research endeavor?
"Affirmative. According to clinicaltrials.gov, the recruitment process for this medical trial is still active; it was initially posted on May 27th 2022 and most recently modified on June 17th 2022. 24 individuals are needed at 1 site."
Is this experiment in search of additional participants at the moment?
"As per the data published on clinicaltrials.gov, this medical trial is currently enrolling participants; it was initially posted on May 27th 2022 and most recently edited June 17th of that same year."
Has the FDA sanctioned Cabozantinib for public use?
"The safety rating for Cabozantinib is a 2 due to the fact that Phase 2 trials have produced evidence of its security, though there are yet no efficacy investigations."
Share this study with friends
Copy Link
Messenger